Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SciClone Pharmaceuticals has recruited first patient in a multicenter, randomized, double-blind, placebo-controlled Phase 2b trial evaluating of SCV-07 for the prevention of oral mucositis (OM).
Subscribe to our email newsletter
SciClone Pharma will recruit around 160 patients who are receiving standard chemoradiation therapy for treatment head and neck cancers.
In the trial, the company expects to evaluate three doses of the drug to investigate its impact on modifying the course of OM in patients with head and neck cancer.
Additionally, the trial will also evaluate the safety and tolerability of the drug.
SciClone Pharma president and CEO Friedhelm Blobel said that they are very pleased with how quickly they have been able to advance the SCV-07 OM program from completion of the phase 2a trial to the initiation of this important phase 2b study.
"We expect that this upcoming study will provide additional information regarding the potential therapeutic role of SCV-07 in the treatment of OM and, in turn, inform SciClone on the best path for designing a possible pivotal Phase 3 trial," Blobel said.